Third article in Paolo's Biotech Notes series. PDF attached and uploaded. Additionally, Paolo has provided a relevant timely article. ContraFect Corp (CFRX) has a promising pipeline with a potential ...

The third quarter was a pivotal period for both the biotech and pharmaceutical sectors, with regulatory developments and an increase in business deals shaping the landscape for the industries. Public ...

Bank of America Securities writes that SMid-cap biotech, companies with small to mid-sized market capitalizations, had a rocky start to the year. Many companies in the coverage are down 20-40% year-to ...

Drug developers aren’t expected to come back to the US equity markets in full force until next year — lagging other industries as biotechnology has delivered only subpar investor returns. Only five ...

Forbes contributors publish independent expert analyses and insights. I write about finance, innovation, climate and sustainability Europe’s next wave of biotech innovation could determine how the ...